Lucis Raises $20 Million for AI-Driven Preventive Health

Lucis, the platform focused on preventive health through the use of artificial intelligence, has announced the completion of a $20 million Series A funding round. This investment brings the total capital raised by the company to $28 million, including a previous $8 million seed round secured just four months ago. The Series A round was led by Singular, with participation from General Catalyst, Y Combinator, and several angel investors, including key figures behind Runna, Céline Lazorthes (Resilience), and Manu Lecomte.

Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis aims to revolutionize the approach to healthcare, shifting the focus from treating illnesses to active prevention. The company seeks to provide individuals with a comprehensive, data-driven understanding of their health status, enabling proactive interventions before symptoms appear. This approach aligns with a growing demand for solutions that empower users to control their health, supported by advanced technologies.

The Platform and AI Approach

The core of Lucis's offering lies in its ability to analyze a wide range of biological data. The platform examines over 110 blood biomarkers, covering crucial areas such as metabolic health, hormone levels, cardiovascular risk, inflammation, and nutrient levels. This data is then integrated into an AI-powered health companion app, which combines test results with longitudinal data and the user's medical context.

AI plays a fundamental role in providing personalized guidance ranging from nutrition to supplementation, lifestyle changes, and recommended follow-up testing. A distinctive aspect is that recommendations are continuously refined as new data becomes available and are always reviewed by physicians. This ensures that users receive not only data analysis but also practical and clinically validated advice, helping them understand what actions to take to improve their well-being.

Concrete Results and Rapid Growth

Lucis has already demonstrated significant results and notable user engagement. Among its over 10,000 users, preliminary data shows that 75% of those who completed a six-month follow-up improved at least three biomarkers without medication. Furthermore, over 80% of users chose to retest, indicating strong and continuous engagement with the platform and their health monitoring. A particularly relevant finding is that at initial testing, 99.9% of users had at least one biomarker outside optimal ranges, often without prior awareness. This highlights how potential health risks can easily go unnoticed without regular and proactive monitoring.

Maxime Berthelot, co-founder and CEO of Lucis, emphasized the devastating impact of late-stage diagnoses, stating: “The science is already there; what’s missing is a system designed to act before symptoms appear. This is why we built Lucis. By combining biomarker data and AI-driven clinical insights, we can catch what the system misses. Europe deserves a healthcare model that doesn’t wait for people to get sick. We are making prevention the default, rather than a privilege.”

Future Prospects and Market Impact

Currently, Lucis is supported by a team of 20 professionals across engineering, clinical, growth, and operations, complemented by a medical board and a growing network of over 10 physicians providing clinical oversight. Since its launch in 2025, the company has grown to over 10,000 users across France, the UK, Ireland, and Portugal, and has delivered over one million biomarker tests. It has also built a community of thousands of members and established partnerships with major laboratory groups, including Eurofins and Randox.

Looking ahead, Lucis plans to expand into Spain, Germany, and Italy by the end of 2026. The company will continue to invest in personalization, longitudinal monitoring, and the clinical safety of its solutions. Jeremy Uzan, co-founder and General Partner at Singular, commented: “Europe’s preventive health category will be won by platforms that unite clinical credibility with AI at scale. Lucis has moved with remarkable velocity, reaching 10,000 users in under a year, delivering measurable outcomes and building a compounding data advantage that sets the standard for the category. We see Lucis as a clear category winner in Europe.” This strategic positioning in the preventive health market, supported by solid funding and proven effectiveness, suggests a significant potential impact on how individuals manage their health in the future.